Sentinel' Identification of Obesity and Tobacco Use in Claims **Compared to Electronic Health Record (EHR) Data** Casie Horgan¹, Po-Yin Chang², Meg Her¹, Rebecca Hawrusik¹, Alexander Peters¹, Catherine Corey², David J. Graham², Judith C. Maro¹ and Noelle M. Cocoros¹

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA ² U.S. Food and Drug Administration, Silver Spring, MD, USA

OBJECTIVES

BACKGROUND

- To examine claims and EHR-based indicators of obesity and tobacco use among sodium-glucose co-transporter-2 inhibitor (SGLT-2i) users in the FDA Sentinel System
- To understand how key characteristics of interest differ in EHR versus claims data

Table 1. EHR Versus Claims-Based BMI/Obesity Data Availability in New SGLT-2i Users

		Presence of a Claims Code for Any BMI or General Obesity Code	
EHR Record for		Yes	No
BMI	Yes	932 (29.5%)	1,004 (31.8%)
	No	420 (13.3%)	799 (25.3%)

Table 2. EHR Versus Claims-Based Tobacco Use Data Availability in New SGLT-2i Users

> of a Claima Cada for Draconco

- Obesity and tobacco use are important covariates for many drug safety questions
- Claims data are expected to undercapture both obesity and tobacco use, leading to misclassification, while EHR data are expected to better identify these characteristics
- The Sentinel Common Data Model includes Vital Signs Clinical Data tables populated via EHR sources. Seven Integrated Delivery Systems populate these data, along with codes from administrative claims diagnoses and procedures

Figure 1. Sentinel Common Data Model's Clinical Data Tables



METHODS

- We identified new SGLT-2i users aged ≥ 20 years, March 2013 through June 2018, and assessed obesity and tobacco use in the 365 days prior to and including index dispensing
- EHR-based body mass index (BMI) was calculated using closest valid height and

		Tobacco Use	
EHR Record for Tobacco Status		Yes	No
	Yes	419 (13.3%)	1,786 (56.6%)
	No	143 (4.5%)	807 (25.6%)

Figure 2. BMI and Obesity Estimates in Claims Versus EHR Data in New SGLT-2i Users

BMI Distribution for Patients with an EHR-based BMI (N=1,936)



BMI/Obesity Distribution for Patients with a Claims-Based Code (N=1,352)







weight records to index and classified as:

Underweight/Normal: $15 \leq BMI < 25$

Overweight: $25 \le BMI < 30$

Obese: 30 ≤ BMI < 40

Severely Obese: $40 \le BMI \le 90$

Claims-based BMI and obesity was defined using the closest diagnosis or procedure code to index. Separate "narrow" and "broad" claims-based obesity definitions were defined as:

Narrow Obesity: presence of a BMI-specific code for BMI ≥ 30

Broad Obesity: presence of a BMI-specific or general obesity code

EHR-based tobacco use was defined by closest populated vital measure to index date using the following categories:

Current User

Never User

Former User





Figure 4. Tobacco Use Concurrence across EHR and Claims Data in New SGLT-2i

Other (includes passive exposure, environmental exposure, conflicting information, and record indicating the patient was not asked)

• Claims-based tobacco use was defined by a diagnosis code for tobacco use or a dispensing for a tobacco cessation product

RESULTS

- We identified 3,155 new SGLT-2i users
- 61% had an EHR-based BMI recorded
- 43% had any claims code for obesity (e.g. ICD-10 code E66.8 for "Other obesity") or BMI (e.g. ICD-10 code Z68.26 for "Body Mass Index (BMI) 26.0-26.9, adult")
- Only 14% of all EHR BMI measures had a *concordant* claims-based code when using the narrow definition of obesity; 44% had a *concordant* claims-based code when using the broad definition of obesity
- 70% had any EHR record for tobacco use; 44% of those records indicated current or former use
- 40% of EHR-based current and former tobacco users had a *concordant* claims code indicating tobacco use

CONCLUSION

- SGLT-2i new users showed good concordance between claims and EHR for current tobacco use
- A more sensitive definition of obesity in claims data increased concordance with EHR data compared to a narrower definition that was BMI-specific
- Characterization of missingness and clinical measurement concordance for key confounders could inform quantitative bias analysis or imputation approaches for future work

ACKNOWLEDGEMENTS/DISCLOSURES

- Disclaimer: The views expressed in this poster reflect those of the authors and should not be construed to represent U.S. FDA views or policies
- This work was supported by the FDA through the Department of Health and Human Services (HHS) Contract number 75F40119D10037
- Many thanks are due to Data Partners who provided data used in the analysis
- The authors have no conflicts of interest to disclose